ULTRAGENYX PHARMACEUTICAL INC. (RARE) Total liabilities 2016–2025
ULTRAGENYX PHARMACEUTICAL INC. (RARE) total liabilities at each fiscal year-end, per SEC filings.
$1.6BFY2025 · since FY2016: $66.7M → $1.6B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $1.6B | +29.3% |
| FY2024 | $1.2B | +2.1% |
| FY2023 | $1.2B | +1.9% |
| FY2022 | $1.2B | +98.9% |
| FY2021 | $599.8M | -0.9% |
| FY2020 | $605.2M | +25.6% |
| FY2019 | $481.7M | +335.4% |
| FY2018 | $110.7M | +3.1% |
| FY2017 | $107.3M | +61.0% |
| FY2016 | $66.7M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More RARE financial trends
RARE RevenueRARE Net incomeRARE Net marginRARE Gross profitRARE Gross marginRARE Operating incomeRARE Operating marginRARE Operating cash flowRARE Free cash flowRARE Capital expendituresRARE Return on equityRARE Stock buybacksRARE Dividends paidRARE Total assetsRARE Shareholders’ equityRARE overview →